Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry).

Completed

• Conditions: bone metastases; Prostate cancer; 10038588

• Registration Number: NL-OMON55579
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- At the physicians discretion
- Written informed consent
- Age 18 year of older

Exclusion Criteria

- At the physicians discretion

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To evaluate the efficacy of Radium-223 treatment in a non-study population by<br /><br>effects on Symptomatic Skeletal Event (SSE)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To Evaluate Radium-223 treatment efficacy by patient reported analgesic use and<br /><br>pain outcome. </p><br>